Table 3 Information on patients that received a targeted therapy based on DNA panel sequencing results
Patient ID | Entity | Therapeutic | Description | Target | Response |
|---|---|---|---|---|---|
sGB_6 | Secondary glioblastoma, IDH-mutant (WHO grade IV) | Cabozantinib | Tyrosine kinase inhibitor | MET AMP, KIT AMP | yes |
MB_2 | Medulloblastoma, SHH-activated/TP53-WT (WHO grade IV) | Vismodegib/ sonidegib | Sonic hedgehog pathway inhibitor | PTCH1 stopgain with a frequency of 92% | yes |
aA_8 | Anaplastic astrocytoma, IDH-wildtype (WHO grade III) | Abemaciclib | CDK4/6 inhibitor | CDK6 AMP | no |
reclassified as: | |||||
Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma (WHO grade IV) |